| Literature DB >> 24433955 |
Jasmijn G M van Kampen1, Monica A J Marijnissen-van Zanten2, Femke Simmer3, Winette T A van der Graaf4, Marjolijn J L Ligtenberg5, Iris D Nagtegaal6.
Abstract
The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Therefore, there is an urgent need for new therapeutic options in pancreatic cancer. In the past years it became evident that deregulation of epigenetic mechanisms plays an important role in pancreatic carcinogenesis. This review focuses on the exploitation of drugs that alter histone modifications, DNA methylation and microRNA expression as options for the treatment of pancreatic cancer.Entities:
Keywords: DNA methyltransferase inhibitor; Epigenetics; Histone deacetylase inhibitor; Histone methyltransferase inhibitor; MicroRNA; Pancreatic cancer; Therapy
Mesh：
Substances：
Year: 2014 PMID： 24433955 DOI： 10.1016/j.ctrv.2013.12.002
Source DB: PubMed Journal: Cancer Treat Rev ISSN： 0305-7372 Impact factor: 12.111